# Jiangsu HengRui Medicine Co., Ltd. trials: 573 (2026)

ClinicalTrials.gov lists 573 trials with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor, 68 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Jiangsu HengRui Medicine Co., Ltd.: 573 rows for $28.65, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 573
- Recruiting or not yet: 68
- Read on: November 19, 2026

## Trials

The 25 newest of 573, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 6, 2026 | NCT07920939 | Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Type 2 Diabetes | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920939) |
| November 3, 2026 | NCT07913061 | A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913061) |
| October 26, 2026 | NCT07894328 | A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Breast Cancer | 1,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894328) |
| September 8, 2026 | NCT07806058 | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | Recruiting | Pancreatic Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806058) |
| September 1, 2026 | NCT07796763 | A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients... | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Not yet recruiting | Advanced Colorectal Cancer Expressing HER2 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796763) |
| August 27, 2026 | NCT07790380 | FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell... | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Recruiting | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With... | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790380) |
| August 12, 2026 | NCT07760831 | A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Moderate to Severe Ulcerative Colitis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760831) |
| August 5, 2026 | NCT07746726 | Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Recruiting | Neuromuscular Blockade | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746726) |
| July 17, 2026 | NCT07711184 | A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Recruiting | Prostate Cancer | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07711184) |
| May 27, 2026 | NCT07610148 | A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Active not recruiting | Breast Cancer | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610148) |
| May 15, 2026 | NCT07588906 | To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy... | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588906) |
| April 29, 2026 | NCT07556822 | Phase I Study of HRS-3005 in B-cell Malignancies | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Recruiting | B-cell Malignancy | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556822) |
| March 27, 2026 | NCT07497386 | A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Recruiting | Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497386) |
| March 27, 2026 | NCT07494175 | Study on the Mass Balance of \[14C\]HRS-9190 for Injection in Healthy Participants | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Active not recruiting | Healthy Adult Male | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494175) |
| March 24, 2026 | NCT07489482 | A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Recruiting | Diabetes Mellitus | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489482) |
| March 16, 2026 | NCT07472725 | A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes... | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Active not recruiting | Diabetes Mellitus, Type 2 | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07472725) |
| March 3, 2026 | NCT07446309 | Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Completed | Neuromuscular Blockade | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446309) |
| March 3, 2026 | NCT07446153 | A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumor | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446153) |
| February 12, 2026 | NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 1/2 | Recruiting | Prostate Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407283) |
| February 11, 2026 | NCT07404579 | Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Completed | Neuromuscular Blockade | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07404579) |
| February 2, 2026 | NCT07380334 | A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07380334) |
| January 28, 2026 | NCT07372924 | A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU) | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Completed | Abirritation in the ICU | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372924) |
| January 23, 2026 | NCT07362355 | The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Recruiting | Primary Gout and Hyperuricemia | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362355) |
| December 31, 2025 | NCT07311694 | A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic... | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Recruiting | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311694) |
| December 16, 2025 | NCT07286032 | A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced... | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Recruiting | Patients With Chemotherapy-Induced Thrombocytopenia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286032) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 278 |
| Phase 1/2 | 39 |
| Phase 2 | 112 |
| Phase 2/3 | 9 |
| Phase 3 | 127 |
| Phase 4 | 5 |
| Not applicable | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 283 |
| Unknown | 159 |
| Recruiting | 55 |
| Terminated | 29 |
| Active not recruiting | 25 |
| Not yet recruiting | 13 |
| Withdrawn | 6 |
| Suspended | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 47 |
| Breast Neoplasms | 21 |
| Carcinoma, Non-Small-Cell Lung | 14 |
| Neoplasms | 14 |
| Prostatic Neoplasms | 12 |
| Hyperuricemia | 11 |
| Ovarian Neoplasms | 11 |
| Pain | 9 |
| Recurrence | 9 |
| Diabetes Mellitus | 8 |
| Stomach Neoplasms | 8 |
| Arthritis, Rheumatoid | 8 |
| Lung Neoplasms | 7 |
| Gout | 6 |
| Colorectal Neoplasms | 6 |
| Nasopharyngeal Carcinoma | 6 |
| Neoplasm Metastasis | 6 |
| Small Cell Lung Carcinoma | 5 |
| Purpura, Thrombocytopenic, Idiopathic | 5 |
| Uterine Cervical Neoplasms | 4 |
| Endometriosis | 4 |
| Carcinoma, Hepatocellular | 4 |
| Thrombosis | 4 |
| Pancreatic Neoplasms | 4 |
| Triple Negative Breast Neoplasms | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Plastic injection molders in the United States](https://specstream.ai/data/businesses/plastic-injection-molders/united-states)
- [Tableware suppliers in the United States](https://specstream.ai/data/businesses/tableware-suppliers/united-states)
- [Art schools in the United States](https://specstream.ai/data/businesses/art-schools/united-states)
- [Civil engineering firms in the United States](https://specstream.ai/data/businesses/civil-engineering-firms/united-states)
- [Fertilizer stores in the United States](https://specstream.ai/data/businesses/fertilizer-stores/united-states)
- [Kitchen remodelers in the United States](https://specstream.ai/data/businesses/kitchen-remodelers/united-states)
